Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02203825 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands
A Phase 1 study, sponsored by Celyad Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT02203825: Completed Phase 1 study, sponsored by Celyad Oncology.
NCT02203825 is a Phase 1 study that has completed, run by Celyad Oncology. The registered enrollment target is 12 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02203825, a Phase 1 study, has completed, sponsored by Celyad Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This Phase I clinical trial is evaluating chimeric-antigen receptor (CAR) T-cells (CM-CS1 T cells) which recognize NKG2D-ligands on the surface of cancer cells. This study evaluates the safety and feasibility of administering a single intravenous dose of CM-CS1 CAR T-cells to patients with AML, MDS-RAEB and Multiple Myeloma.
Primary Outcome
Safety will be defined by the occurence of study-related serious and non-serious adverse events. Feasibility will be defined by the frequency of subjects enrolled who do not receive CM-CS1 T-cells.
Interventions
- BIOLOGICAL CM-CS1 T-cell infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2015-03 |
| Est. Completion | 2018-03 |
| Phase | Phase 1 |
What the finished NCT02203825 record still lists
NCT02203825 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 1 intervention - of which CM-CS1 T-cell infusion is the first listed.
NCT02203825 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02203825 about?
NCT02203825 is a clinical study titled "Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands". This Phase I clinical trial is evaluating chimeric-antigen receptor (CAR) T-cells (CM-CS1 T cells) which recognize NKG2D-ligands on the surface of cancer cells. This study evaluates the safety and feasibility of administering a single intravenous dose of CM-CS1 CAR T-cells to patients with AML, MDS-...
What is the current status of trial NCT02203825?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2015-03. Estimated completion is 2018-03.
What interventions are being tested in trial NCT02203825?
The interventions under investigation include: CM-CS1 T-cell infusion (BIOLOGICAL).
Who is sponsoring clinical trial NCT02203825?
This trial is sponsored by Celyad Oncology, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02203825's enrollment target sits among peer trials
12 1852nd of 2000 higher than 90 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia